TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 recep...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Palmblad, Jan, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Mauritzson, Nils, Westin, Jan, Samuelsson, Jan, Birgegård, Gunnar
Médium: Artigo
Jazyk:Inglês
Vydáno: Ivyspring International Publisher 2008
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2293642/
https://ncbi.nlm.nih.gov/pubmed/18414650
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky